Unlocking the True Value of Multiplexing IHC – From Clinical Trial Programs Through to IVD Applications
Related
This exclusive webinar provides leaders in pharma and biotech with an opportunity to explore the potential and the long-term aspirations of mIHC for clinical trials and IVD applications.
Providing perspectives from leading experts in the field, viewers can gain the latest insights on how to overcome the challenges of getting mIHC ready for IVD use and discussed how to successfully incorporate and speed up the use of mIHC in their clinical trial settings.
Webinar objectives:
- Realizing the potential of using mIHC for clinical trials and how to overcome the challenges of getting it ready for IVD use
- Discovering the value of the right antibody content to warrant mIHC and the importance of the reagent and panel validation
- Strategizing for long-term aspirations: Understanding how pharma can be supported with content, assay development and assay deployment to speed up use of mIHC in clinical trial settings and how to work towards a successful global deployment and seamless incorporation of this technology into your process for robust and reproducible large-scale adoption
Presenters:
- Angela Vasaturo, Associate Director of Biomarker Strategy and Applications | Ultivue
- Keith Wharton, VP Medical Director | Ultivue
- Oliver Stoss, Chief Executive Officer | Targos Inc.
- Will Howat, Senior Director of Antibody Validation & Characterization | Abcam
Do you have any questions about this webinar? Contact us at events@abcam.com